News
01-17-2014, 10:00 AM
Research led by the Translational Genomics Group at Vall d'Hebron Institute of Oncology (VHIO) in Barcelona has not only shown that HER2+ breast cancer can be classified into four different subtypes, but also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.
More... (http://www.medicalnewstoday.com/releases/271351.php)
More... (http://www.medicalnewstoday.com/releases/271351.php)